Navigation Links
Computational analysis identifies drugs to treat drug-resistant breast cancer
Date:7/31/2012

HEIDELBERG, 31 July 2012 Researchers have used computational analysis to identify a new Achilles heel for the treatment of drug-resistant breast cancer. The results, which are published in Molecular Systems Biology, reveal that the disruption of glucose metabolism is an effective therapeutic strategy for the treatment of tumours that have acquired resistance to front-line cancer drugs such as Lapatinib.

"The growth and survival of cancer cells can often be impaired by treatment with drugs that interfere with the actions of one or more oncogenes," said Prahlad Ram, the senior author of the study and Professor at the University of Texas MD Anderson Cancer Center, Houston, Texas. "However, the clinical benefits to patients are often short lived due to acquired drug resistance. Finding alternative intervention points or so-called new addictions for cancer cells is of critical importance for designing novel therapeutic strategies against tumours. Our results reveal specific new targets for drug intervention in the metabolic pathways of cancer cells and identify existing drugs that can be used to treat drug-resistant cancer."

Lapatinib is used for the treatment of patients with advanced or metastatic breast cancer in cases where tumours overexpress the ErbB2 gene. The ErbB2 gene provides instructions for making a specific growth factor receptor. If too much of this ErbB2 growth factor receptor is made, it can lead to cells that grow and divide continuously, one of the defining characteristics of breast cancer.

The scientists used microarrays to measure gene expression in breast cancer cells with and without treatment with Lapatinib. Computational analysis of more than 15000 gene interactions revealed four major populations of genes that were regulated in a significant way. Three of these groups were the regular suspects related to drug resistance, such as genes involved in oxidation and reduction reactions or cell cycle processes. A fourth group comprised a network of reactions linked to the deprivation of glucose.

Analysis of the gene expression networks of ErbB2-positive breast cancer patients revealed that the glucose deprivation network is linked to low survival rates of the patients. Computational screening of a library of existing drugs for therapeutics that target the glucose deprivation response identified several drugs that could be effective in treating drug-resistant breast cancer.

"By developing novel gene expression analysis algorithms and integrating diverse data, we have been able to look beyond changes in the immediate molecular signaling pathways of breast cancer cells and to consider the wider system of molecular networks within the cell," remarked Ram. "Our approach predicts new uses for existing drugs that impact the metabolism of breast cancer cells and may offer an expedient route to improved treatments for breast cancer patients."

The glucose-deprivation response network counteracts EGFR signalling in lapatinib resistant cells


'/>"/>
Contact: Barry Whyte
barry.whyte@embo.org
49-622-188-91108
European Molecular Biology Organization
Source:Eurekalert  

Related medicine news :

1. Lung Cancer Screening Might Pay Off, Analysis Shows
2. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. Zinc Pills May Shorten Colds, Analysis Suggests
5. Biochip-based device for cell analysis
6. Analysis will examine safety of in-hospital underwater births
7. Genome-wide analysis shows previously undetected abnormalities in parents of affected children
8. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
9. Meta-analysis: Interventions improve depression in cancer patients
10. Terrorism and the Olympics by-the-numbers: Analysis from UMD-based START
11. Genome analysis of brain tumors showing the way to new treatment strategies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Computational analysis identifies drugs to treat drug-resistant breast cancer
(Date:5/22/2017)... ... May 22, 2017 , ... An inventor from Columbia, S.C., ... pen. "My wife’s hand was damaged in a firework accident, so she couldn’t grip ... with manual problems." , He then designed and created a prototype for the HELPEN ...
(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pot. Reefer. Grass. Mary Jane. No matter ... share its attributes like never before. More than a map, new social marketplace ... stores, strains, products – and for the first time – each other. A social ...
(Date:5/21/2017)... ... May 21, 2017 , ... Dental visits ... six months since you've seen a dentist, it's time for a dental checkup. ... x-rays once per year. , Dental checkups are a relatively easy procedure that ...
(Date:5/19/2017)... ... ... Springfield, Vermont-based law firm of Brady/Callahan has released a new Personal Injury law ... Personal Injury Attorney, " the article offers insight for people who have questions, concerns ... someone is injured due to another person's negligence, they may want to ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... 4, 2017  Fortuna Fix Inc. (" Fortuna "), ... first to eliminate the need for embryonic and fetal stem ... neurodegenerative diseases. Fortuna announced today the ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald , ... and Professor James Giordano , PhD. "We ...
(Date:5/4/2017)... 4, 2017  A new tight-tolerance microextrusion medical ... highly-engineered materials, is being launched by Natvar, a ... developed in recent years to service a wide ... applications. More expensive materials such as glass and ... due to their ability to consistently hold tolerances. ...
(Date:5/3/2017)... 3, 2017  West Pharmaceutical Services, Inc. (NYSE: ... injectable drug administration, announced today that Fran ... Services, and Diane Paskiet , Director, Scientific ... focused on West,s expertise in the areas of ... as providing commentary on updated industry guidance. ...
Breaking Medicine Technology: